Literature DB >> 1376807

Interaction of atrial natriuretic peptide with DA1 receptors in preconstricted isolated perfused rat lungs.

M J Polak1, J T Romano, D A Taylor.   

Abstract

Using an in situ isolated salt-perfused rat lung preparation, we investigated the pulmonary vascular response to atrial natriuretic peptide (ANP). ANP was infused in graded doses ranging from 0.01 to 100.0 micrograms/kg during prostaglandin F2 alpha-induced pulmonary vasoconstriction. These experiments were repeated after selective dopamine1 (DA1) receptor blockade with SCH 23390 and after catecholamine depletion by reserpine. ANP at doses of 0.01, 0.1, 1.0, 10.0, or 100.0 micrograms/kg was injected into the pulmonary artery (n = 5-7/dose). In the unblocked group ANP infusion resulted in a dose-dependent decrease in the mean pulmonary arterial pressure (PAP) with a maximum effect at 10 micrograms/kg (delta PAP = -3.4 +/- 0.2 mm Hg). In the DA1 blockade groups the ANP dose-response curve was shifted to the right, in a parallel fashion. After catecholamine depletion with reserpine, the ANP dose-response curve was identical to that of the unblocked groups. With the parallel, rightward shift of the ANP dose-response curves by SCH 23390 and no attenuation of ANP effect after catecholamine depletion, it appears that ANP vasoactive properties in the pulmonary vasculature involve an interaction with the vascular DA1 receptors. This observation differs from the ANP-dopaminergic interactions seen in the kidney in which ANP action depends on endogenous dopamine transmission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376807     DOI: 10.1097/00005344-199206000-00006

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Effect of urodilatin on platelet-activating factor-induced bronchoconstriction, vasoconstriction and edema formation in isolated rat lung.

Authors:  S Uhlig; R L Featherstone; O H Wilhelms; A Wendel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.